A. V. Oskolkov

A. V. Oskolkov

Auto-generated profile, based on publicly available information

A. V. Oskolkov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in MD-Onco
Verified
Journal Article
Open access
PDF file
VGV. E. Gruzdev
V. E. Gruzdev
MAM. A. Anisimov
M. A. Anisimov
YRYu. E. Ryabukhina
Yu. E. Ryabukhina
AOA. V. Oskolkov
A. V. Oskolkov
PZP. A. Zeynalova
P. A. Zeynalova
ЮРЮ. Е. Рябухина
Ю. Е. Рябухина
Therapy of chronic pain syndrome and adequate perioperative pain management during treatment of malignant neoplasms are important problems at the current stage of clinical medicine development. Currently, multimodal pain management is effectively applied through drugs of various pharmacological groups prescribed depending on pain intensity in accordance with a digital rating scale. Associated adverse events as well as impossibility of using peroral or transdermal forms in some cases, limit the use of opioid analgesics. High bioavailability and fast absorption of μ1-opioid receptor agonist tafalgin shown during preclinical studies, relatively favorable safety profile allowed to use this drug in oncological clinic.An experience of using tafalgin in treatment of pain syndrome in patients with malignant tumors at the “Lapino” clinical hospital since 2022 is presented. The effectiveness of the drug is evaluated, and its niche in multimodal pain management is determined.

19 November 2021 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Open access
PDF file
MKMark Kurtser
Mark Kurtser
ESE. I. Spiridonova
E. I. Spiridonova
STS. V. Tsarenko
S. V. Tsarenko
PBP. M. Bagdasaryan
P. M. Bagdasaryan
EBE. A. Baranova
E. A. Baranova
ЮКЮ. Ю. Кутакова
Ю. Ю. Кутакова
Опыт применения вено-венозной экстракорпоральной мембранной оксигенации у беременной с тяжелым острым респираторным дистресс-синдромом, вызванным вирусом SARS-CoV-2

7 December 2023 in MD-Onco
Verified
Journal Article
Open access
PDF file
AOA. V. Oskolkov
A. V. Oskolkov
MAM. V. Antonets
M. V. Antonets
PBP. M. Bagdasaryan
P. M. Bagdasaryan
GOG. A. Ovsyannikov
G. A. Ovsyannikov
Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure which can occur in people of any age. It comprises about 10 % of all admissions in intensive care units. The cornerstone of treatment of severe forms of this disorder is protective mechanical ventilation but in patients with initial hypoxia and/or hypotension tracheal intubation is associated with the risk of significant hemodynamic abnormalities. Mortality from severe forms of ARDS remains high. COVID-19 pandemic led to worldwide wider use of such techniques of respiratory support as high-flow nasal oxygen therapy and non-invasive ventilation, the necessity of which is proposed to be used as one of classifying signs of ARDS in addition to the Berlin criteria. If the respiratory therapy is ineffective, veno-venous extracorporeal membrane oxygenation is used for gaseous exchange and decreasing undesirable effects of high pressure in the respiratory pathways. The success of its application strongly depends on the optimal timing of its initialization. The performance of this technique is associated with a number of complications (hemorrhage, thrombosis, sepsis, etc.). Effective treatment of ARDS requires utilization of a large amount of resources and educated staff.